Late-stage immuno-oncology company, OncoSec Medical Incorporated, is honing in on the development and commercialization of intra-tumoral DNA-based therapeutics aimed to boost anti-tumor immune responses for cancer treatment. The firm's product pipeline includes KEYNOTE-695, currently undergoing Phase 2 trials for advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, in the midst of a Phase 1 clinical trial for COVID-19 treatment; and TAVO + epacadostat + pembrolizumab, which is undergoing Phase 1 clinical trial for squamous cell carcinoma head and neck cancer treatment. Additionally, its pipeline comprises TAVO + nivolumab, which is still in Phase 2 clinical trial for breast cancer treatment; TAVO + CXCL9 for treating solid tumors; and OMS-100 and OMS-102, subject to Phase 2 clinical trials for the treatment of metastatic melanoma. OncoSec Medical has entered into clinical trial collaborations with Merck & Co., Inc. and its subsidiary for KEYNOTE-695 and KEYNOTE-890, and with Duke University's Center for Applied Therapeutics for assessing TAVO in combination or sequentially with a HER2-plasmid vaccine. Once named NetVentory Solutions Inc., OncoSec Medical was renamed in 2011 and is headquartered in New Jersey's Pennington.